DR ANTHONY MELVIN CRASTO,WorldDrugTracker, helping millions, A 90 % paralysed man in action for you, I am suffering from transverse mylitis and bound to a wheel chair,With death on the horizon, This will not stop me, Gods call only..........
DR ANTHONY MELVIN CRASTO Ph.D ( ICT, Mumbai) , INDIA 29Yrs Exp. in the feld of Organic Chemistry,Working for GLENMARK PHARMA at Navi Mumbai, INDIA. Serving chemists around the world. Helping them with websites on Chemistry.Million hits on google, world acclamation from industry, academia, drug authorities for websites, blogs and educational contribution

Monday, 12 October 2015

ROOPA RAI


Roopa Rai

Roopa Rai

Sr. Director, Medicinal Chemistry at Medivation
https://www.linkedin.com/pub/roopa-rai/1/681/578
roopa.rai@medivation.com


Medivation , Inc. 
201 Spear Street 3Rd Floor
San Francisco , California 94105
United States 
Medivation, Inc. is a biopharmaceutical company with small molecule drugs in clinical development to treat three medical needs: Alzheimer’s disease, Huntington’s disease and castration-resistant prostate cancer. The Company has formed separate subsidiaries to hold the product candidates it is developing. The Company’s subsidiary Medivation Neurology, Inc. holds its Dimebon technology, and its subsidiary Medivation Prostate Therapeutics, Inc. holds its MDV300 series technology. 

Experience



Sr. Director, Medicinal Chemistry

Medivation
January 2014 – Present (1 year 10 months)San Francisco Bay Area


Director, Medicinal Chemistry

Medivation
August 2012 – Present (3 years 3 months)San Francisco


Principal Scientist

Celera Genomics
1996 – 2006 (10 years)


Senior Scientist

Axys Pharmaceuticals
1996 – 2002 (6 years)
 




Patents

HETEROCYCLIC COMPOUNDS AND METHODS OF USE

Application number: 20150065519
Abstract: This disclosure provides compounds and methods of using those compounds to treat metabolic disorders and hyperproliferative disorders, including administration of the compounds in conjunction with hormone receptor antagonists.
Type: Application
Filed: August 28, 2014
Issued: March 5, 2015
Inventors: Sarvajit Chakravarty, Roopa Rai, Son Minh Pham, Brahmam Pujala, Ramniwas Jangir, Rambabu Guguloth, Vijay Kumar Sharma

2-(2-HYDROXYBIPHENYL-3-YL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE DERIVATIVES AS FACTOR VIIA INHIBITORS

Application number: 20140378453
Abstract: The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders, cancer or rheumatoid arthritis. Processes for preparing these inhibitors are also disclosed.
Type: Application
Filed: June 27, 2014
Issued: December 25, 2014
Inventors: Aleksandr KOLESNIKOV, Roopa RAI, William Dvorak SHRADER, Steven M. TORKELSON, Kieron E. WESSON, Wendy B. YOUNG

FACTOR VIIA INHIBITOR

Application number: 20140221667
Abstract: The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders, cancer or rheumatoid arthritis. Processes for preparing these inhibitors are also disclosed.
Type: Application
Filed: April 11, 2014
Issued: August 7, 2014
Assignee: Pharmacyclics, Inc.
Inventors: Daniel A. DICKMAN, Dange Vijay KUMAR, Colin O'BRYAN, Roopa RAI, William Dvorak SHRADER

2-(2-hydroxybiphenyl-3-yl)-1H-Benzoimidazole-5-carboxamidine derivatives as factor VIIA inhibitors

Patent number: 8778625
Abstract: The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders, cancer or rheumatoid arthritis. Processes for preparing these inhibitors are also disclosed.
Type: Grant
Filed: September 7, 2012
Issued: July 15, 2014
Assignee: Pharmacyclics, Inc.
Inventors: Aleksandr Kolesnikov, Roopa Rai, William Dvorak Shrader, Steven M. Torkelson, Kieron E. Wesson, Wendy B. Young

FUSED PYRIMIDINE COMPOUNDS AND USE THEREOF

Application number: 20140179668
Abstract: Fused pyrimidine compounds as kinase inhibitors, such as multi-kinase inhibitors, are provided. Fused pyrimidine compounds as IGF-IR inhibitors are provided. The compounds may be used in a method of treating cancer. Pharmaceutical compositions containing a fused pyrimidine compound and a pharmaceutically acceptable carrier are also provided, as are kits containing a fused pyrimidine compound or salt thereof and instructions for use, e.g., in a method of treating cancer.
Type: Application
Filed: December 26, 2013
Issued: June 26, 2014
Assignee: MEDIVATION TECHNOLOGIES, INC.
Inventors: Sarvajit CHAKRAVARTY, Roopa RAI, Michael John GREEN

Factor VIIa inhibitor

Patent number: 8729117
Abstract: The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders, cancer or rheumatoid arthritis. Processes for preparing these inhibitors are also disclosed.
Type: Grant
Filed: September 20, 2012
Issued: May 20, 2014
Assignee: Pharmacyclics, Inc.
Inventors: Daniel A. Dickman, Dange Vijay Kumar, Colin O'Bryan, Roopa Rai, William Dvorak Shrader

Anti-viral compounds, compositions, and methods of use

Patent number: 8729077
Abstract: Disclosed are compounds, stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, their preparation, use, and compositions thereof for treating an infection mediated at least in part by a virus in the Flaviviridae family of viruses.
Type: Grant
Filed: November 19, 2009
Issued: May 20, 2014
Assignee: GlaxoSmithKline LLC
Inventors: Frank Ulrich Schmitz, Roopa Rai, Christopher Don Roberts, Wieslaw Kazmierski, Richard Grimes

FACTOR VIIA INHIBITOR

Application number: 20140080879
Abstract: The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders, cancer or rheumatoid arthritis. Processes for preparing these inhibitors are also disclosed.
Type: Application
Filed: September 20, 2012
Issued: March 20, 2014
Assignee: PHARMACYCLICS, INC.
Inventors: Daniel A. Dickman, Dange Vijay Kumar, Colin O'Bryan, Roopa Rai, William Dvorak Shrader

2-(2-Hydroxybiphenyl-3-yl)-1H-Benzoimidazole-5-Carboxamidine Derivatives as Factor VIIA Inhibitors

Application number: 20130157298
Abstract: The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders, cancer or rheumatoid arthritis. Processes for preparing these inhibitors are also disclosed.
Type: Application
Filed: September 7, 2012
Issued: June 20, 2013
Assignee: Pharmacyclics, Inc.
Inventors: Aleksandr Kolesnikov, Roopa Rai, William Dvorak Shrader, Steven M. Torkelson, Kieron E. Wesson, Wendy B. Young

Factor VIIa inhibitor

Patent number: 8415328
Abstract: The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders, cancer or rheumatoid arthritis. Processes for preparing these inhibitors are also disclosed.
Type: Grant
Filed: May 3, 2011
Issued: April 9, 2013
Assignee: Pharmacyclics, Inc
Inventors: Daniel A. Dickman, Dange Vijay Kumar, Colin O'Bryan, Roopa Rai, William Dvorak Shrader, Kieron Wesson

2-(2-hydroxybiphenyl-3-yl)-1-benzoimidazole-5-carboxamidine derivatives as factor VIIa inhibitors

Patent number: 8299110
Abstract: The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders, cancer or rheumatoid arthritis. Processes for preparing these inhibitors are also disclosed.
Type: Grant
Filed: May 3, 2011
Issued: October 30, 2012
Assignee: Pharmacyclics, Inc.
Inventors: Aleksandr Kolesnikov, Roopa Rai, William Dvorak Shrader, Steven M. Torkelson, Kieron E. Wesson, Wendy B. Young

2-(2-HYDROXYBIPHENYL-3-YL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE DERIVATIVES AS FACTOR VIIA INHIBITORS

Application number: 20110269806
Abstract: The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders, cancer or rheumatoid arthritis. Processes for preparing these inhibitors are also disclosed.
Type: Application
Filed: May 3, 2011
Issued: November 3, 2011
Assignee: Pharmacyclics, Inc.
Inventors: Aleksandr Kolesnikov, Roopa Rai, William Dvorak Shrader, Steven M. Torkelson, Kieron E. Wesson, Wendy B. Young

Anti-Viral Compounds, Compositions, And Methods Of Use

Application number: 20110224211
Abstract: Disclosed are compounds, stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, their preparation, use, and compositions thereof for treating an infection mediated at least in part by a virus in the Flaviviridae family of viruses.
Type: Application
Filed: November 19, 2009
Issued: September 15, 2011
Inventors: Frank Ulrich Schmitz, Roopa Rai, Christopher Ron Roberts, Wieslaw Kazmierski, Richard Grimes

FACTOR VIIA INHIBITOR

Application number: 20110207939
Abstract: The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders, cancer or rheumatoid arthritis. Processes for preparing these inhibitors are also disclosed.
Type: Application
Filed: May 3, 2011
Issued: August 25, 2011
Assignee: Pharmacyclics, Inc.
Inventors: Daniel A. Dickman, Dange Vijay Kumar, Colin O'Bryan, Roopa Rai, William Dvorak Shrader, Kieron Wesson

Anti-Viral Compounds, Compositions, And Methods Of Use

Application number: 20110044943
Abstract: Disclosed are compounds of Formula (I), pharmaceutically acceptable salts and solvates thereof, compositions thereof, and methods for their preparation and uses for treating viral infections mediated at least in part by a virus in the Flaviviridae family of viruses.
Type: Application
Filed: July 11, 2008
Issued: February 24, 2011
Inventors: Martin Robert Leivers, Jesse Daniel Keicher, Franz Ulrich Schmitz, Roopa Rai, Ryan Lauchli, Sebastian Reinhard Johannes Liehr, Stephanie Anna Chan, Tony Loc Ton

2-5A ANALOGS AND THEIR METHODS OF USE

Application number: 20100331397
Abstract: Disclosed herein are compounds that activate RNaseL, methods of synthesizing compounds that activate RNaseL and the use of compounds that activate RNaseL for treating and/or ameliorating a disease or a condition, such as a viral infection, a bacterial infection, cancer and/or parasitic disease.
Type: Application
Filed: June 23, 2010
Issued: December 30, 2010
Assignee: ALIOS BIOPHARMA, INC.
Inventors: Leonid Beigelman, Lawrence Blatt, Harri Lönnberg, Roopa Rai, Guangyi Wang, Thomas Horn, Julian Symons, Antitsa Simitrova Stoycheva, Dean Ng, Jerome Deval

Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections

Application number: 20100204265
Abstract: Provided are certain chemical entities, pharmaceutical compositions, and methods of treatment of a member of the flaviviradae family of viruses such as hepacivirus (Hepatitis C or HCV).
Type: Application
Filed: February 9, 2009
Issued: August 12, 2010
Inventors: Subramanian Baskaran, Jack Maung, Martin Leon Neitzel, Roopa Rai, Irina Slododov, Vincent W-F Tai

Amido Anti-Viral Compounds, Compositions, And Methods Of Use

Application number: 20100061960
Abstract: Disclosed are compounds, stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, their preparation, use, and compositions thereof for treating an infection mediated at least in part by a virus in the Flaviviridae family of viruses.
Type: Application
Filed: July 16, 2009
Issued: March 11, 2010
Inventors: Franz Ulrich Schmitz, Roopa Rai, Ronald Griffith, Christopher Don Roberts

N-(5-Membered Aromatic Ring)-Amido Anti-Viral Compounds

Application number: 20100004441
Abstract: Disclosed are compounds having Formula (I) and the compositions and methods thereof for treating or preventing a viral infection mediated at least in part by a virus in the Flaviviridae family of viruses, wherein A, R2, m, R, V, W, T, Z, R1, Y, and p are disclosed herein.
Type: Application
Filed: August 20, 2009
Issued: January 7, 2010
Inventors: Franz Ulrich Schmitz, Christopher Don Roberts, Ali Dehghani Mohammad Abadi, Ronald Conrad Griffith, Martin Robert Leivers, Irina Slobodov, Roopa Rai

ANTI-VIRAL INHIBITORS AND METHODS OF USE

Application number: 20090317360
Abstract: Disclosed are compounds and compositions of Formula (I), pharmaceutically acceptable salts and solvates thereof, and their uses for treating viral infections mediated at least in part by a virus in the Flaviviridae family of viruses.
Type: Application
Filed: June 11, 2008
Issued: December 24, 2009
Inventors: Roopa Rai, Franz Ulrich Schmitz, Christopher Don Roberts, Irina Slobodov, Martin Robert Leivers

N-(5-membered aromatic ring)-amido anti-viral compounds

Patent number: 7595398
Abstract: Disclosed are compounds having Formula (I) and the compositions and methods thereof for treating or preventing a viral infection mediated at least in part by a virus in the Flaviviridae family of viruses, wherein A, R2, m, R, V, W, T, Z, R1, Y, and p are disclosed herein.
Type: Grant
Filed: December 12, 2006
Issued: September 29, 2009
Assignee: SmithKline Beecham Corporation
Inventors: Franz Ulrich Schmitz, Christopher Don Roberts, Ali Dehghani Mohammad Abadi, Ronald Conrad Griffith, Martin Robert Leivers, Irina Slobodov, Roopa Rai

ANTI-VIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE

Application number: 20090226398
Abstract: Disclosed are compounds and compositions of Formula (I), pharmaceutically acceptable salts and solvates thereof, and their preparation and uses for treating viral infections mediated at least in part by a virus in the Flaviviridae family of viruses.
Type: Application
Filed: March 3, 2009
Issued: September 10, 2009
Inventors: Martin Robert Leivers, Christopher Don Roberts, Sebastian Johannes Reinhard Liehr, Stephanie Anna Chan, Roopa Rai, Ryan Lauchli, Son Minh Pham, Vivek Kumar Rajwanshi, Tony Loc Ton, Adam Christopher Villa

ANTI-VIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE

Application number: 20090197880
Abstract: Disclosed are compounds of Formula (I), pharmaceutically acceptable salts and solvates thereof, compositions thereof, and methods for their preparation and uses for treating viral infections mediated at least in part by a virus in the Flaviviridae family of viruses.
Type: Application
Filed: January 12, 2009
Issued: August 6, 2009
Inventors: Martin Robert Leivers, Jesse Daniel Keicher, Franz Ulrich Schmitz, Roopa Rai, Ryan Lauchli, Sebastian Reinhard Johannes Liehr, Stephanie Anna Chan, Tony Loc Ton, Son Minh Pham, Adam Christopher Villa

Certain nitrogen containing bicyclic chemical entities for treating viral infections

Application number: 20090176778
Abstract: Provided are certain chemical entities, pharmaceutical compositions, and methods of treatment of a member of the flaviviradae family of viruses such as hepacivirus (Hepatitis C or HCV).
Type: Application
Filed: August 8, 2008
Issued: July 9, 2009
Inventors: Franz Ulrich Schmitz, Vincent W-F Tai, Roopa Rai, Christopher Don Roberts, Ali Dehghani Mohammad Abadi, Subramanian Baskaran, Irina Slobodov, Jack Maung, Martin Leon Neitzel

Anti-viral compounds, compositions, and methods of use

Application number: 20090074717
Abstract: Disclosed are compounds of Formula (I), pharmaceutically acceptable salts and solvates thereof, compositions thereof, and methods for their preparation and uses for treating viral infections mediated at least in part by a virus in the Flaviviridae family of viruses.
Type: Application
Filed: July 11, 2008
Issued: March 19, 2009
Inventors: Martin Robert Leivers, Jesse Daniel Keicher, Franz Ulrich Schmitz, Roopa Rai, Ryan Lauchli, Sebastian Reinhard Johannes Liehr, Stephanie Anna Chan, Tony Loc Ton

2-(2-Hydroxybiphenyl-3-yl)-1H-Benzoimidazole-5-Carboxamidine Derivatives as Factor VIIA Inhibitors

Application number: 20090054432
Abstract: The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders, cancer or rheumatoid arthritis. Processes for preparing these inhibitors are also disclosed.
Type: Application
Filed: October 21, 2008
Issued: February 26, 2009
Assignee: Pharmacylics, Inc. A Delaware Corporation
Inventors: Aleksandr KOLESNIKOV, Roopa Rai, William Dvorak Shrader, Steven M. Torkelson, Kieron E. Wesson, Wendy B. Young

2-(2-hydroxybiphenyl-3-yl)-1H-benzoimidazole-5-carboxamidine derivatives as factor VIIA inhibitors

Patent number: 7479502
Abstract: The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders, cancer or rheumatoid arthritis. Processes for preparing these inhibitors are also disclosed.
Type: Grant
Filed: December 3, 2003
Issued: January 20, 2009
Assignee: Pharmacyclics, Inc.
Inventors: Aleksandr Kolesnikov, Roopa Rai, William Dvorak Shrader, Steven M. Torkelson, Kieron E. Wesson, Wendy B. Young

Factor Viia Inhibitor

Application number: 20080275250
Abstract: The present invention relates to novel inhibitors or Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders, cancer or rheumatoid arthritis. Processes for preparing these inhibitors are also disclosed.
Type: Application
Filed: June 2, 2005
Issued: November 6, 2008
Assignee: PHARMACYCLICS, INC.
Inventors: Daniel A. Dickman, Dange Vijay Kumar, Colin O'Bryan, Roopa Rai, William Dvorak Shrader, Kieron Wesson

Amido Anti-viral Compounds

Application number: 20080181866
Abstract: Disclosed are compounds, stereoisomers, tautomers, pharmaceutically acceptable salts, or prodrugs thereof of having Formula (I), their preparation, use, and compositions thereof for treating an infection mediated at least in part by a virus in the Flaviviridae family of viruses, wherein A, R3, X, V, W, T, Z, R, Y1, and p are as defined herein.
Type: Application
Filed: November 20, 2007
Issued: July 31, 2008
Inventors: Martin Robert Leivers, Franz Ulrich Schmitz, Ronald Conrad Griffith, Christopher Don Roberts, Ali Dehghani Mohammad Abadi, Stephanie Anna Chan, Roopa Rai, Irina Slobodov, Tony Loc Ton

ANTIVIRAL AGENTS

Application number: 20070287699
Abstract: Compounds are provided having utility for the treatment of viral infections, particularly HCV.
Type: Application
Filed: April 30, 2007
Issued: December 13, 2007
Assignee: ViroBay, Inc.
Inventors: Dange Kumar, Roopa Rai, Wendy Young, Huiyong Hu, Jennifer Riggs, Tony Ton, Michael Green, Barry Hart, Kenneth Brameld, Jeffrey Dener

N-(5-MEMBERED AROMATIC RING)-AMIDO ANTI-VIRAL COMPOUNDS

Application number: 20070265265
Abstract: Disclosed are compounds having Formula (I) and the compositions and methods thereof for treating or preventing a viral infection mediated at least in part by a virus in the Flaviviridae family of viruses, wherein A, R2, m, R, V, W, T, Z, R1, Y, and p are disclosed herein.
Type: Application
Filed: December 12, 2006
Issued: November 15, 2007
Inventors: Franz Schmitz, Christopher Roberts, Ali Dehghani Abadi, Ronald Griffith, Martin Leivers, Irina Slobodov, Roopa Rai

Antiviral agents

Application number: 20070032522
Abstract: The present invention is directed to compounds that are antiviral agents. Specifically the compounds of the present invention inhibit replication of HCV and are therefore useful in treating hepatitis C infections. The present invention is also directed to pharmaceutical compositions comprising these compounds and processes for preparing them.
Type: Application
Filed: June 28, 2006
Issued: February 8, 2007
Inventors: Dange Kumar, Roopa Rai

2-(2-Hydroxybiphenyl-3-yl)-1h-benzoimidazole-5-carboxamidine derivatives as factor viia inhibitors

Application number: 20060205942
Abstract: The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders, cancer or rheumatoid arthritis. Processes for preparing these inhibitors are also disclosed.
Type: Application
Filed: December 3, 2003
Issued: September 14, 2006
Inventors: Aleksandr Kolesnikov, Roopa Rai, William Shrader, Steven Torkelson, Kieron Wesson, Wendy Young

2-[5-(5-carbamimidoyl-1h-heteroaryl)]-6-hydroxybiphenyl-3-yl derivatives as factor viia inhibitors

Application number: 20050203094
Abstract: The present invention provides 2-[5-(5-carbamimidoyl-1H-heteroaryl)]-6-hydroxy-biphenyl-3-yl derivatives of formula (I): I That are Factor VIIa and Xa inhibitors
Type: Application
Filed: February 12, 2003
Issued: September 15, 2005
Inventors: Aleksandr Kolesnikov, Roopa Rai, Dvorak Shrader, Wendy Young

2-[5-(5-Carbamimidoyl-1H-heteroaryl)-6-hydroxybiphenyl-3-YL]-succinic acid derivatives as factor viia inhibitors

Application number: 20050176797
Abstract: The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders. Processes for preparing these inhibitors are also disclosed.
Type: Application
Filed: September 13, 2004
Issued: August 11, 2005
Assignee: AXYS PHARMACEUTICALS, INC.
Inventors: Huiyong Hu, John Hendrix, Aleksandr Kolesnikov, Roopa Rai, William Shrader, David Sperandio, Wendy Young, Steven Torkelson

(Hetero)aryl-bicyclic heteroaryl derivatives, their preparation and their use as protease inhibitors

Patent number: 6867200
Abstract: The present invention provides novel compounds of the Formula (I): A-B, its prodrug forms, or pharmaceutically acceptable salts thereof, wherein A represents a saturated, unsaturated, or a partially unsaturated bicyclic heterocyclic ring structure, and B represents an aryl or a heteroaryl group. Preferred compounds of the present invention comprise a benzimidazole or indole nucleus. The compounds of this invention are inhibitors of serine proteases, Urokinase (uPA), Factor Xa (FXa), and/or Factor VIIa (FVIIa), and have utility as anti cancer agents and/or as anticoagulants for the treatment or prevention of thromboembolic disorders in mammals.
Type: Grant
Filed: December 17, 1999
Issued: March 15, 2005
Assignee: Axys Pharmaceuticals, Inc.
Inventors: Darin A. Allen, Jason M. Hataye, Witold N. Hruzewicz, Aleksandr Kolesnikov, Richard L. Mackman, Roopa Rai, Spencer R. Jeffrey, Erik J. Verner, Wendy B. Young, William Dvorak Shrader

Non-amidine containing protease inhibitors

Application number: 20030225036
Abstract: The present invention provides novel compounds of the Formula (I) its prodrug forms, or pharmaceutically acceptable salts thereof. Preferred (I) compounds of the present invention comprise a pyrrolo pyridinyl, pyrrolo pyrimidinyl or indole nucleus. The compounds of this invention are inhibitors of Factor Xa (FXa), Factor VIIa (FVIIa) and/or serine proteases, Urokinase (uPA), and have utility as anti-coagulants for the treatment or prevention of thromboembolic disorders in mammals and as anticancer agents.
Type: Application
Filed: March 24, 2003
Issued: December 4, 2003
Inventors: Aleksandr Kolesnikov, Roopa Rai

2- [5- (5-carbamimidoyl-1H-heteroaryl)-6-hydroxybiphenyl-3-yl]-succinic acid derivatives as factor viia inhibitors

Application number: 20030114457
Abstract: The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders. Processes for preparing these inhibitors are also disclosed.
Type: Application
Filed: July 3, 2002
Issued: June 19, 2003
Assignee: Axys Pharmaceuticals, Inc.
Inventors: Huiyong Hu, John Hendrix, Aleksandr Kolesnikov, Roopa Rai, William Dvorak Shrader, David Sperandio, Wendy Young, Steve Torkelson
 
/////////////Roopa Rai, Sr. Director, Medicinal Chemistry,  Medivation
Posted by at No comments:
Labels: , , ,

Sunday, 11 October 2015

Wendy Young, Vice President, Discovery Chemistry at Genentech


Wendy Young

Wendy Young

Vice President, Discovery Chemistry at Genentech
Ensuring that we have a culture that supports innovation and provides access to the most cutting edge approaches and tools is key. Just as important is that we continue to recruit and retain the brightest chemists on the planet.
LINKS
https://www.linkedin.com/pub/wendy-young/2/157/65a
Wendy B. Young,
young.wendy@gene.com
Genentech Inc. 1 DNA Way MS#18 South San Francisco, CA 94080 Phone: 650-467-7945 young.wendy@gene.com\
Wendy Young, Ph.D., Director, Discovery Chemistry, Genentech
Wendy B. Young has nineteen years of industrial drug discovery experience, having led discovery efforts at both small biotech firms (Axys/Celera and Scios: 1995-2006) and larger companies (Genentech/Roche: 2006-present). Wendy is currently Director of Medicinal Chemistry at Genentech, where she is a leader of project teams and directs a large group of medicinal chemists.
These teams have produced multiple clinical candidates, from a variety of target classes, currently under clinical evaluation in a range of indications.
She was recently elected as Vice Chair of the ACS Medicinal Chemistry (ACS MEDI) Division which will culminate in her being Chair of the Division in 2017.
Wendy received her Ph.D. from Princeton University under the direction of E.C. Taylor and carried out Postdoctoral Studies at Memorial Sloan Kettering Cancer Center with Professor Samuel Danishefsky.
Wendy is listed as an inventor or author on over 65 patent and research publications and has given presentations at many national and international meetings.
Wendy Young - Vice President, Small Molecule Discovery Chemistry
http://www.gene.com/scientists/our-scientists/wendy-young
"We all know friends and family members that have suffered with serious illness. It can be devastating. My goal, alongside my colleagues, is to discover agents that will treat these patients. The motto "patients are waiting" really hits home with everyone."
I was drawn to join Genentech, in 2006, because of its reputation for doing excellent science and employing strong teamwork. At Genentech, any team member with a compelling idea gets a chance to be heard and access to the resources to move their idea forward. The organization is also very nimble and open-minded to incorporate processes to accelerate discovery and development. Today, I am Vice President of Discovery Chemistry, overseeing a highly talented and experienced group of medicinal, computational and analytical chemists. These Genentech chemists are integral on our project teams to innovate and discover the next generation of medicines to treat patients in need. What excites me the most is that, at Genentech, we have the brightest people, tools, and know-how to continue to make huge strides in solving complex biological and medical issues. It is a huge opportunity and responsibility to shape the future treatments for patients in need.

FEATURED PUBLICATION

Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis. Nature Chemical Biology, 2011, ISSN: 1552-4469 Di Paolo, J.; Huangm T.; Balazs, M.; Barbosa, J.; Barck, K.; Bravo, B.;Carano, R.; Darrow, J.; Davies, D.; DeForge, L.; Diehl, L.; Ferrando,R.; Gallion, S.; Giannetti, A.; Gribling, P.; Hurez, V.; Hymowitz, S.; Jones, R.; Kropf, J.; Lee, W.; Maciejewski, P.; Mitchell, S.; Rong, H.; Staker, B.; Whitney, A.; Yeh, S.; Young, W.; Yu, C.; Zhang, J.; Reif,K.; Currie, K. View Abstract on PubMed

Experience




Vice President, Discovery Chemistry

Genentech
January 2015 – Present (10 months)



Senior Director, Discovery Chemistry

Genentech
October 2014 – Present (1 year 1 month)



Director, Discovery Chemistry

Genentech
November 2012 – Present (3 years)



Senior Director, Medicinal Chemistry

Celera
1995 – 2006 (11 years)



Postdoctoral Fellow

Sloan-Kettering Cancer Center
1993 – 1995 (2 years)
Advisor: Samuel Danishefsky Design and total synthesis of the anti-cancer agent Taxol®

Education




Princeton University

PhD, Chemistry
1988 – 1993
Advisor: E.C. Taylor Dissertation: Design and Synthesis of Folate Analogs as Novel Anti-Cancer Agents



Wake Forest University

BA, MS, Chemistry
1984 – 1989
Advisor: Huw M.L. Davies: Thesis: Novel Entry into the Tropane Alkyloid Ring System Via Reactions of Vinyl Carbenoids and Pyrroles"
  • Sloan Kettering Cancer Center, American Cancer Society, Postdoctoral Fellow – 1995
  • Princeton University, Ph.D. Chemistry – 1993
  • Wake Forest University, B.A./M.S. Chemistry, cum laude – 1988
  • AWARDS
    • Elected Chair of National ACS MEDI – 2017
    • Elected Program Chair of National ACS MEDI – 2015-2016
    • Elected Vice Chair of National ACS MEDI – 2014
    • American Cancer Society Postdoctoral Fellowship – 1993-1995
    • H. W. Dodds - Princeton University Honorific Fellowship, Top Thesis Award – 1993
    • Josephine de Karman Fellowship – 1992
    • ACS Graduate Fellowship sponsored by Lilly Research Laboratories – 1991-1992
    • Department of Education Graduate Fellowship – 1990
    • BA/MS Chemistry Scholarship, Wake Forest University – 1988

  • Potent and selective Bruton's tyrosine kinase inhibitors: Discovery of GDC-0834

    Bioorganic & medicinal chemistry letters, 2015, ISSN: 0960-894X
    Young, Wendy B; Barbosa, James; Blomgren, Peter; Bremer, Meire C; Crawford, James J; Dambach, Donna; Gallion, Steve; Hymowitz, Sarah G; Kropf, Jeffrey E; Lee, Seung H; Liu, Lichuan; Lubach, Joseph W; Macaluso, Jen; Maciejewski, Pat; Maurer, Brigitte; Mitchell, Scott A; Ortwine, Daniel F; Di Paolo, Julie; Reif, Karin; Scheerens, Heleen; Schmitt, Aaron; Sowell, C Gregory; Wang, Xiaojing; Wong, Harvey; Xiong, Jin-Ming; Xu, Jianjun; Zhao, Zhongdong; Currie, Kevin S
    View on PubMed

  • 3-Heterocyclyl quinolone inhibitors of the HCV NS5B polymerase

    Bioorganic and Medicinal Chemistry Letters, 1 January 2012, v22, p300-304, ISSN: 0960-894X.
    Kumar, Dange V.; Rai, Roopa; Brameld, Ken A.; Ton, Tony L.; Riggs, Jennifer; Somoza, John R.; Rajagopalan, Ravi; Janc, James W.; Xia, Yu M.; Hu, Huiyong; Young, Wendy B.; Lehoux, Isabelle; Ho, Joseph D.; Hart, Barry; Green, Michael J.
    View on PubMed

  • Significant Species Difference in Amide Hydrolysis of GDC-0834, a Novel Potent and Selective Bruton's Tyrosine Kinase (BTK) Inhibitor

    Drug metabolism and disposition: the biological fate of chemicals, {Drug-Metab-Dispos}, 8 Jul 2011 (epub: 8 7 2011), ISSN: 1521-009X.
    Liu, Lichuan; Halladay, Jason; Shin, Young; Wong, Susan; Coraggio, Melis; La, Hank; Baumgardner, Matthew; Le, Hoa; Gopaul, Sashi; Boggs, Jason; Kuebler, Peter; Davis, John; Liao, Charlene; Lubach, Joseph; Deese, Alan; Sowell, Gregory; Currie, Kevin; Young, Wendy; Khojasteh, Cyrus; Hop, Cornelis; Wong, Harvey
    View on PubMed

  • Pyrazolopyridine Inhibitors of B-Raf<sup>V600E</sup>. Part 1: The Development of Selective, Orally Bioavailable, and Efficacious Inhibitors.

    ACS Medicinal Chemistry Letters, 2011, ISSN: 1948-5875
    Wenglowsky, Steve; Ren, Li; Ahrendt, Kateri; Laird, Ellen; Aliagas, Ignacio; Alicke, Bruno; Buckmelter, Alex; Choo, Edna; Dinkel, Victoria; Feng, Bainian; Gloor, Susan; Gould, Stephen; Gross, Stefan; Gunzner-Toste, Janet; Hansen, Joshua; Hatzivassiliou, Georgia; Liu, Bonnie; Malesky, Kim; Mathieu, Simon; Newhouse, Brad; Raddatz, Nicholas; Ran, Yingqing; Rana, Sumeet; Randolph, Nikole; Risom, Tyler; Rudolph. Joachim; Savage, Scott; Selby, LeAnn; Shrag, Michael; Song, Kyung; Sturgis, Hillary; Voegtli, Walter; Wen, Zhaoyang; Willis, Brandon; Woessner, Richard; Wu, Wen-I; Young, Wendy; Grina, Jonas
    View on PubMed

  • Quinolones as HCV NS5B Polymerase Inhibitors

    Bioorganic & Medicinal Chemistry Letters, 2011,
    Kumar, Dange; Rai, Roopa; Brameld, Ken; Somoza, John; Rajagopalan, Ravi; Janc, James; Xia, Yu; Ton, Tony; Shaghafi, Michael; Hu, Huiyong; Lehoux, Isabelle; To, Nhat; Young, Wendy; Green, Michael;
    View on PubMed

  • Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis

    Nature Chemical Biology, 2010, ISSN: 1552-4469
    Di Paolo, Julie; Huang, Tao; Balazs, Mercedesz; Barbosa, James; Barck, Kai; Bravo, Brandon; Carano, Richard; Darrow, James; Davies, Douglas; DeForge, Laura; Diehl, Lauri; Ferrando, Ronald; Gallion, Steven; Giannetti, Anthony; Gribling, Peter; Hurez, Vincent; Hymowitz, Sarah; Jones, Randall; Kropf, Jeffrey; Lee, Wyne; Maciejewski, Patricia; Mitchell, Scott; Rong, Hong; Staker, Bart; Whitney, Andrew; Yeh, Sherry; Young, Wendy; Yu, Christine; Zhang, Juan; Reif, Karin; Currie, Kevin
    View on PubMed
CLIPS.........

Influential Women 2015: Wendy Young

Wendy Young, Ph.D.

Vice president, discovery chemistry, Genentech



Influential Women 2015
Influential Women 2015

Education: B.A., M.S., chemistry, Wake Forest University; Ph.D., chemistry, Princeton University.
Proudest professional accomplishment: I was team leader for seven years on an important drug development project where there’s a lot of industry competition. We had to overcome many obstacles but I believed in the project and in the science and wouldn’t give up. We ultimately discovered the root of the problem and presented the data to regulators, and they allowed us to move the medicine into the clinic. Our team emerged as a really tight-knit group because we wouldn’t give up as we had a strong passion for the end goal. It was a great example of how perseverance is key.




How to help women in business advance: What I’ve learned is that to succeed, you must have achievement. You’ll get more visibility by racking up achievements. Don’t be distracted by sideline activities because it takes away time and energy from things that will really matter. Be brave. Speak up. Figure out how to find your voice.
Dream super power: To not need sleep.
Surprising fact about you: I love to hula hoop!
http://berkeleysciencereview.com/piper-promotes-isp-seminar-with-dr-wendy-young-genentech/



September 19, 2012 ·
  
 
 
Dr. Wendy Young. — at College Of Chemistry - UC Berkeley.

.................................................................................

Executive Committee




Regular Executive Committee Members


Program Chair 2015-2016

Wendy B. Young, Ph.D. Vice President, Discovery Chemistry Genentech Inc. 1 DNA Way MS#18 South San Francisco, CA 94080 Phone: 650-467-7945 young.wendy@gene.com ..................................................................................
  The University of Toledo

MEDICINAL & BIOLOGICAL CHEMISTRY

https://www.utoledo.edu/pharmacy/depts/mbc/MAGSS/keynote.html
Guest Speaker and Panelist
Dr. Wendy Young, Director of Medicinal Chemistry, Genentech; Vice Chair, ACS Medicinal Chemistry Division
Photo of Wendy Young Genentech
Wendy B. Young has twenty years of drug discovery experience, having led discovery efforts at both small biotech firms (Axys/Celera and Scios: 1995-2006) and larger companies (Genentech/Roche: 2006-present). Wendy is currently Director of Medicinal Chemistry at Genentech, where she is a leader of project teams and directs a large group of medicinal chemists. These teams have produced multiple clinical candidates, from a variety of target classes, currently under clinical evaluation in a range of indications. Wendy received her Ph.D. from Princeton University in chemistry under the direction of E.C. Taylor and was an American Cancer Society Postdoctoral Fellow at Memorial Sloan Kettering Cancer Center with Professor Samuel Danishefsky. Wendy is listed as an inventor or author on over 65 patent and research publications and has given presentations at many national and international meetings. Wendy was recently elected as Vice Chair of the ACS Medicinal Chemistry (ACS MEDI) Division which will culminate in her being Chair of the Division in 2017.



Discovery and SAR of new Btk inhibitors that bind to the Btk ATP-binding cleft.

FromSpecific Btk inhibition suppresses B cell– and myeloid cell–mediated arthritis

Nature Chemical Biology,7,41–50(2011)
doi:10.1038/nchembio.481

.............................................

Project Details:

Highlights in Medicinal Chemistry - Short Course to postgraduate students of the summer school at the Federal University of Rio de Janeiro (UFRJ)

Project No.: 2014-022-1-700
Start date: 2014-09-01
End date: 0000-00-00
Division: Chemistry and Human Health Division

...............
  https://www.google.com.ar/patents/WO2010056875A1?cl=en














//////////Wendy Young, Vice President, Discovery Chemistry, Genentech
Posted by at No comments:
Labels: , , ,

Saturday, 10 October 2015

Chun-Yu HO

.




Ph.D
Professor (Associate)
, Shenzhen · Chemistry


Dr. Chun-Yu Ho received his Ph.D. in 2005, for his development in the area of organocatalytic asymmetric epoxidation, under the supervision of Prof. Dan Yang in The University of Hong Kong (HKU). After pursing post-doctoral research for transition metal catalysis with Prof. Timothy F. Jamison during 2005-07 in Massachusetts Institute of Technology (MIT), he started his independent career at The Chinese University of Hong Kong (CUHK) as a Research Assistant Professor in 2007. Now he is an Associate Professor in South University of Science and Technology of China (SUSTC) and Adjunct AP of CUHK.




Research Experience

  • Sep 2007–Dec 2015
    RAP
    The Chinese University of Hong Kong · Department of Chemistry · Dr. Chun-Yu HO
    Hong Kong · Hong Kong
  • Sep 2005–Jun 2007
    Post doc affiliate
    Massachusetts Institute of Technology · Department of Chemistry
    United States · Cambridge
  • Sep 2000–Jul 2005
    PhD Student
    The University of Hong Kong · Department of Chemistry · Prof. Dan Yang
    Hong Kong · Hong Kong















  1. Center of Novel Functional Molecules, Department of Chemistry, The Chinese University of Hong Kong, Shatin, NT, Hong Kong SAR (China)
*Center of Novel Functional Molecules, Department of Chemistry, The Chinese University of Hong Kong, Shatin, NT, Hong Kong SAR (China)

Dr. Ho shared his recent breakthrough in the area of alkene chemistry during the 5th International Conference on Cutting-Edge Organic Chemistry in Asia (ICCEOCA-5), 7-11 November 2010. He has been selected by the coordinator of Japan to receive an ACP Lectureship Award and invited to deliver a series of lectures in 2011.
The presented work complements the P-Ni-H catalyzed alkene dimerization (for monoenes) and olefin cross-metathesis technology (for internal olefins), provides the first highly selective catalytic route to synthesize unsymmetric geminal disubstituted alkenes directly from two different types of monosubstituted olefins (http://en.wikipedia.org/wiki/Alkene). US Patent filed on 16 Feb 2010 via TLO, CUHK.
For further details about that work, please visit:
Angew. Chem. Int. Ed. 2010, 49, 9182.
http://onlinelibrary.wiley.com/doi/10.1002/anie.201001849/abstract
For the story behind the scene & the potential in regard to synthetic organic chemistry, please see:
SYNFACTS 2011, SYNFORM A15.
https://www.thieme-connect.com/ejournals/pdf/synfacts/doi/10.1055/s-0030-1259399.pdf
the certificate of Asian Core Program (ACP) Lectureship Prof. C. Y. Ho received 

Research Interests：
**Organometallic Chemistry
N-Heterocyclic Carbene and its applications in OMCOS
Develop novel, practical, green and energy efficient methodology for:
◆ Organic chemical library synthesis and polymerization;
◆ Sustainable organic/hybrid materials preparations and applications;
◆ Phosphonylation and cyanation to access important biological cpds & their subsequent SAR studies.
Professional Experience：
◆ 2013 Associate Professor, South University of Science and Technology of China (SUSTC)
◆ 2013 Adjunct AP, The Chinese University of Hong Kong (CUHK)
◆ 2007 Research Assistant Professor, The Chinese University of Hong Kong (CUHK)
Educational Background：
◆ 2005 Postdoctoral Affiliate, Massachusetts Institute of Technology (MIT)
◆ 2000 Postgraduate Student, The University of Hong Kong (HKU)
Honors & Awards：
◆ 2013 American Chemical Society (ACS) Excellence in Science Symposium:
The Journal of Organic Chemistry and Organic Letters Best Poster Award
◆ 2013 Invited presentation in International Symposium of Organic Reaction Mechanism,
a Celebration in Honor of Grubbs, Houk, Schleyer & Truhlar
◆ 2013 Recognized as Overseas High-Caliber Personnel
(Peacock Program Awardee from Shenzhen Government)
◆ 2013 Adjunct AP at The Chinese University of Hong Kong
◆ 2012 Editorial Member of Natural Products Chemistry & Research Journal
◆ 2012 Invited as one of the three oversea lecturers in
3rd Symposium of Molecular Activation Directed toward Straightforward Synthesis,
at Hanamaki, Iwate (MEXT, Japan)
◆ 2012  Thousand Young Talents Program Awardee (1,1-Disubstituted Olefin Synthesis)
◆ 2012 Faculty of Science Postgraduate Student Research Output Award (Ms Lisi He)
◆ 2012 Publication honored in RSC ChemComm. Emerging Investigator Issue 2012
◆ 2011 Asian Core Program Lectureship Award (from Singapore)
◆ 2010 Asian Core Program Lectureship Award (from Japan)
◆ 2005 The Croucher Foundation Fellowship
Selected publications： * Denoted as the Corresponding Author
Representative Seminal Publications:
◆ “Shuffle off the Classic Beta-Si Elimination by Ni-NHC Cooperation: Implication for C-C Forming Reactions Involving Ni-Alkyl-Beta-Silanes.”
Ho, C.-Y.*; He, L. Chem. Commun. 2012, 48, 1481.

Honored in RSC ChemComm Emerging Investigator Issue 2012
◆ “Catalytic Intermolecular Tail-to-Tail Hydroalkenylation of Styrenes with alpha Olefins: Regioselective Migratory Insertion Controlled by a Nickel/N-Heterocyclic Carbene.”

Ho, C.-Y.*; He, L. Angew. Chem. Int. Ed. 2010, 49, 9182.
Highlighted thrice in:
SynForm 2011, issue 2, A15-16 (by Prof. Matteo Zanda);
SynFacts 2011, issue 3, 310 (by Prof. Paul Knochel & Andreas K. Steib).
Organic Chemistry Highlights, 2011, Functionalization and Homologation of Alkenes (by Prof. D. F. Taber).
◆ “Cyanative Alkene-Aldehyde Coupling: Ni(0)-NHC-Et2AlCN Mediated Chromanols Synthesis with High cis-Selectivity at room temperature”
Ho, C.-Y.* Chem. Commun. 2010, 46, 466.
◆ “Alpha-Olefins as Alkenylmetal Equivalents in Catalytic Conjugate Addition Reactions.”
Ho, C.-Y.; Ohmiya, H.; Jamison, T. F.* Angew. Chem. Int. Ed. 2008, 47, 1893.
◆ “Highly Selective Coupling of Alkenes and Aldehydes Catalyzed by NHC–Ni–P(OPh)3: Synergy Between a Strong σ-Donor and a Strong π-Acceptor.”
Selected as Hot Paper by Editors of Angewandte Chemie and published in advance of the Communication for their importance in a rapidly evolving field of high current interest:
Ho, C.-Y.; Jamison, T. F.* Angew. Chem. Int. Ed. 2006, 45, DOI: 10.1002/anie.200603907.
Angew. Chem. Int. Ed. 2007, 46, 782. Angew. Chem. 2007, 46, 796.
◆ “Nickel-Catalyzed Coupling of Alkenes, Aldehydes, and Silyl Triflates.”
Ng, S.-S.; Ho, C.-Y.; Jamison T. F.* J. Am. Chem. Soc. 2006, 128, 11513.
◆ “Nickel-Catalyzed, Carbonyl-Ene-Type Reactions: Selective for Alpha Olefins and More Efficient with Electron-Rich Aldehydes.”
Ho, C.-Y.; Ng, S.-S.; Jamison, T. F.* J. Am. Chem. Soc. 2006, 128, 5326.
Invited Reviews as Corresponding Author:
◆ “NHC-NiH Reactions with Simple Olefins: Advances in Hydroalkenylation, Polymerization, and Ionic Liquid Synthesis.”
Ho, C.-Y.*; He, L.; Chan, C.-W. Synlett 2011, SynPacts issue, 1649.
◆ “Catalytic Addition of Simple Alkenes to Carbonyl Cpds Using Group 10 Metals”
Ho, C.-Y. *; Schleicher, K. D.; Chan, C.-W.; Jamison, T. F.* Synlett 2009, 2565.
Collaborative Research Publications:
◆ "In Vitro Anti-acetylcholinesterase Activities and Permeabilities of Novel Potential Anti-Alzheimer's Agents".
Qian, S.; Mak, M.; He, L.; Ho, C.-Y.*; Han, Y.* and Zuo, Z.* Paper presented in the 9th International ISSX Meeting, organized by International Society for the Study of Xenobiotics. Istanbul, Turkey.
◆ “Nitrile assisted, Brosted acid catalyzed regio and stereoselective diarylphosphonylation of allyl silyl ethers”
Ho, C-Y.*; Chan, C.-W.; Wo, S-K.; Zuo, Z.*; Chan, L.-Y. Org. Biomol. Chem. 2010, 8, 3480.
◆ "Structure-activity and structure-permeability relationships of novel anti-Alzheimer’s agents tacrine dimers".

Qian, S.; He, L.; Mak, M.; Ho, C.-Y.*; Han, Y.* and Zuo, Z.* Paper presented in the 2011 AAPS Annual Meeting and Exposition, organized by The American Association of Pharmaceutical Scientists. Washington, DC, USA.
◆ "Development of LC/MS/MS method for determination of a novel tacrine dimer HLS-3 in rat plasma and its application to pharmacokinetic study".
◆ Qian, S.; He, L.; Wo, S-K.; Mak, M.; Han, Y.*; Ho, C-Y.*; Zuo, Z.* Paper presented in the 2012 AAPS Annual Meeting and Exposition, organized by The American Association of Pharmaceutical Scientists, USA.
Book Chapter:
◆ “NHC-Ni Hydride Catalyzed Terminal Disubstituted Alkene Synthesis”
Ho, C.-Y.*; He, L. ISBN 978-3-8465-0051-4, 88pgs
US Regular Patents:
◆ “Terminal 1,1-Disubstituted Olefin, Methods of Making and Using Thereof”
Solo Inventor: Ho, C.-Y.* US8383873B2 (Granted)
◆ “Process for Preparing Organometalloids”
Solo Inventor: Ho, C.-Y.* US8354554B2 (Granted)
Research Grants:
◆ HK GRF and UGC
◆ Young Thousand Talents Program (Chinese Central Government)
◆ NSFC (Young Program)
Other Info：
Professional Services:
◆ Serve as a reviewer of the following journals:
Angewandte Chemie
Chemistry An Asian Journal
Chemistry An European Journal
Journal of the American Chemical Society (JACS)
Journal of Organometallic Chemistry
Organic Letters
Synthesis
Synlett
◆ Serve as an Editorial member of the Journal below:
Natural Products Chemistry & Research Journal
http://www.esciencecentral.org/journals/editorialboardNPCR.php
Awards received by the students:
◆ Asian Core Program (ACP), Junior Workshop on Cutting-Edge Organic Chemistry in Asia Poster Award (2010 in Taiwan).
◆ Hong Kong Graduate Symposium Poster Award (Organic Chemistry Section).
   Awarded by Hong Kong Graduate Symposium Committee (2011)
◆ Hong Kong PhD Fellowship. Awarded by UGC (2011)
◆ Faculty of Science Postgraduate Student Research Output Award (2011, one per year).
◆ Madam Wong Siew Khoon Scholarship, nominated by the Science Faculty Scholarship Committee as CUHK representative (2012, one per year).
In the Campus News:
◆ http://www.sustc.edu.cn/cn/press/campusnews/campusnews-20130326165601/
◆ http://www.sustc.edu.cn/en/press/campusnews/20131024153010/
Contacts：
◆ Email邮箱：jasonhcy@sustc.edu.cn
◆ College 书院: 致仁书院


 


 Poster Award at the Junior Workshop on Cutting-Edge Organic Chemistry in Asia, organized by National Tsing Hua University and National Science Council, ...




////////////
Posted by at No comments:
Labels:
Subscribe to: Posts (Atom)